Neurotech International

Neurotech International Tangible Book Value per Share

Tangible Book Value per Share of Neurotech International (NTI.AX) as of Oct 27, 2026.

Tangible Book Value per Share

0.00AUD

YoY

-79.32%

Last updated:

Tangible Book Value per Share of Neurotech International is 2026 0.00 AUD. Tangible Book Value per Share of Neurotech International was 2025 0.00 AUD. It decreases by -79.32% lower compared to the previous year.

The Neurotech International Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2019
0.00 AUD
Jan 1, 2020
-0.00 AUD
Jan 1, 2021
0.00 AUD
Jan 1, 2022
0.00 AUD
Jan 1, 2023
0.00 AUD
Jan 1, 2024
0.01 AUD
Jan 1, 2025
0.00 AUD
Jan 1, 2026
0.00 AUD
The Neurotech International Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
0.00AUD-79.32%
0.00AUD-75.17%
0.01AUD+200.32%
0.00AUD+177.06%
0.00AUD-62.97%
0.00AUD-697.48%
-0.00AUD-317.30%
0.00AUD-88.52%
0.00AUD-9.31%
0.00AUD-56.74%
0.01AUD+1,183.03%
0.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurotech International Stock analysis

What does Neurotech International do? Neurotech International Ltd. generates revenue through the development and commercialization of medical devices and solutions, primarily targeting pediatric neurological disorders. The company's key product, Mente Autism, is a portable EEG headband that uses closed-loop neurofeedback to assist children with autism spectrum disorder (ASD) by improving relaxation and engagement. Clinical studies assess the neuro-protective and anti-inflammatory effects of its NTI/Dolce cannabis strains, which are part of its development program NTI164 that completed a Phase I/II trial for ASD treatment. The firm focuses on commercializing these neurological solutions for pediatric use in home therapy settings. The company's primary customers are families and healthcare providers managing children with autism spectrum disorder (ASD). Mente Autism is marketed as a home therapy device to increase engagement and reduce anxiety in autistic children with elevated delta-band brain activity. Neurotech International Ltd. leverages its clinical trial results to support the commercialization of Mente Autism and its NTI/Dolce cannabis strains, which are positioned as therapeutic solutions for neurological conditions. The firm's revenue streams are derived from the sale of Mente Autism devices and the potential future commercialization of its NTI/Dolce cannabis-based products. Neurotech International Ltd. operates within the medical device sector, emphasizing pediatric neurological solutions. Its products, including Mente Autism and the NTI/Dolce cannabis strains, are developed through clinical studies to address specific neurological disorders. The company's focus on home-based therapy for ASD patients differentiates its offerings in the market, targeting a niche segment of families seeking non-invasive, accessible treatments for children with autism. Neurotech International is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurotech International stock

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Neurotech International since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neurotech International

All Key Metrics — Neurotech International